These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 8729907)
41. Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line. Fei R; Shaoyang L Gynecol Oncol; 2002 Apr; 85(1):40-4. PubMed ID: 11925118 [TBL] [Abstract][Full Text] [Related]
42. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Mizutani Y; Yoshida O; Bonavida B J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929 [TBL] [Abstract][Full Text] [Related]
43. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065 [TBL] [Abstract][Full Text] [Related]
44. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. Soda G; Antonaci A; Bosco D; Nardoni S; Melis M J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183 [TBL] [Abstract][Full Text] [Related]
45. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation. Meenakshi A; Kumar RS; Kumar NS Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421 [TBL] [Abstract][Full Text] [Related]
46. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Schiffer IB; Gebhard S; Heimerdinger CK; Heling A; Hast J; Wollscheid U; Seliger B; Tanner B; Gilbert S; Beckers T; Baasner S; Brenner W; Spangenberg C; Prawitt D; Trost T; Schreiber WG; Zabel B; Thelen M; Lehr HA; Oesch F; Hengstler JG Cancer Res; 2003 Nov; 63(21):7221-31. PubMed ID: 14612517 [TBL] [Abstract][Full Text] [Related]
47. An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer. Arafat WO; Gómez-Navarro J; Xiang J; Barnes MN; Mahasreshti P; Alvarez RD; Siegal GP; Badib AO; Buchsbaum D; Curiel DT; Stackhouse MA Mol Ther; 2000 Jun; 1(6):545-54. PubMed ID: 10933979 [TBL] [Abstract][Full Text] [Related]
48. c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells. Dong J; Naito M; Tsuruo T Oncogene; 1997 Aug; 15(6):639-47. PubMed ID: 9264404 [TBL] [Abstract][Full Text] [Related]
49. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547 [TBL] [Abstract][Full Text] [Related]
50. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334 [TBL] [Abstract][Full Text] [Related]
51. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Bartholomeusz C; Itamochi H; Nitta M; Saya H; Ginsberg MH; Ueno NT Oncogene; 2006 Jan; 25(1):79-90. PubMed ID: 16170361 [TBL] [Abstract][Full Text] [Related]
52. Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits. Tagliaferri P; Tortora G; Guarrasi R; Damiano V; Ruggiero A; Morelli D; Caraglia M; Bianco R; di Isernia G; Pepe S; Arteaga CL; Langton-Webster BC; Bianco AR; Ciardiello F Clin Cancer Res; 1996 Jan; 2(1):207-14. PubMed ID: 9816108 [TBL] [Abstract][Full Text] [Related]
53. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. Stackhouse MA; Buchsbaum DJ; Grizzle WE; Bright SJ; Olsen CC; Kancharla S; Mayo MS; Curiel DT Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):817-22. PubMed ID: 9845103 [TBL] [Abstract][Full Text] [Related]
54. Eradication of c-erbB-2-Positive Ovarian Cancer Cells Mediated by Intracellular Expression of Anti-c-erbB-2 Antibody. Deshane J; Alvarez RD; Siegal GP Methods Mol Med; 2001; 39():757-68. PubMed ID: 21340837 [TBL] [Abstract][Full Text] [Related]
55. The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv. Grim J; Deshane J; Siegal GP; Alvarez RD; DiFiore P; Curiel DT J Mol Med (Berl); 1998 May; 76(6):451-8. PubMed ID: 9625302 [TBL] [Abstract][Full Text] [Related]
56. pcDNA3.1(-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth. He P; Zhu D; Hu JJ; Peng J; Chen LS; Lu GX Mol Biol Rep; 2010 Mar; 37(3):1597-604. PubMed ID: 19444644 [TBL] [Abstract][Full Text] [Related]
57. Targeting the function of the HER2 oncogene in human cancer therapeutics. Moasser MM Oncogene; 2007 Oct; 26(46):6577-92. PubMed ID: 17486079 [TBL] [Abstract][Full Text] [Related]
58. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Moasser MM Oncogene; 2007 Oct; 26(45):6469-87. PubMed ID: 17471238 [TBL] [Abstract][Full Text] [Related]